Zoldonrasib

Phase 3Small molecule

Revolution Medicines

Zoldonrasib is one of 67 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerRecruiting

Solid TumorRecruiting

Pancreatic CancerPhase 3

Recruiting

Solid TumorPreclinical

Recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Zoldonrasib

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

Merck & Co.

Preclinical

1 5

Medrol

Pfizer

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

LDE225

Novartis

Preclinical

1 9

Chemotherapy Agents

Takeda

Preclinical

1 10

Rybelsus

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Solid Tumor

NCT07397338

Q2 2030

Phase 3Recruiting

Pancreatic Cancer

NCT07621718

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT07621718·670 enrolled

Solid Tumor1 trial

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Preclinical·NCT07397338·370 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Zoldonrasib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zoldonrasib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zoldonrasib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revolution Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Revolution Medicines

Zoldonrasib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q2 2030

Trials by Indication[1]

Pancreatic Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News